Package Leaflet: Information for the User
Rocuronium Tamarang 10 mg/ml Solution for Injection and Perfusion EFG
Rocuronium, bromide
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
Contents of the package leaflet:
Rocuronium Tamarang belongs to a group of medicines called muscle relaxants. Muscle relaxants are used during an operation as part of a general anesthetic. When you undergo an operation, your muscles must be completely relaxed. This makes it easier for the surgeon to perform the operation. Normally, nerves send messages to muscles through impulses. Rocuronium Tamarang works by blocking these impulses so that the muscles relax. Because your respiratory muscles also relax, you will need help breathing (artificial ventilation) during and after the operation until you can breathe on your own again.
During the operation, your anesthesiologist will control the effect of the muscle relaxant and, if necessary, give you more. At the end of the surgery, the effects of the medicine are allowed to wear off, and you will start breathing on your own. Sometimes, the anesthesiologist will give you another medicine to help speed up this process.
Rocuronium Tamarang can also be used in the Intensive Care Unit for short-term use to keep your muscles relaxed.
You must not be given Rocuronium Tamarang
Tell your anesthesiologist if this applies to you
Warnings and precautions
Talk to your anesthesiologist before you are given Rocuronium Tamarang
Some conditions may affect the effects of Rocuronium Tamarang, for example:
If you have any of these conditions, your anesthesiologist will take them into account when deciding the correct dose of Rocuronium Tamarang for you.
Children and elderly
Rocuronium Tamarang can be used in children (newborns and adolescents) and the elderly, but your anesthesiologist must evaluate your medical history first.
Other medicines and Rocuronium Tamarang
Tell your anesthesiologist if you are taking,have recently taken, or might take any other medicines. Rocuronium Tamarang may affect other medicines or be affected by them.
Medicines that increase the effect of Rocuronium Tamarang:
Medicines that decrease the effect of Rocuronium Tamarang:
Additionally, you may be given other medicines before or during surgery that may alter the effects of rocuronium. These include certain anesthetics, other muscle relaxants, medicines such as phenytoin, and medicines that reverse the effect of Rocuronium Tamarang. Rocuronium may make certain anesthetics work more quickly. Your anesthesiologist will take this into account when deciding the correct dose of Rocuronium Tamarang for you.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your anesthesiologist before you are given this medicine.
It is possible that your anesthesiologist will give you this medicine, but first, they must discuss it with you. You may be given Rocuronium Tamarang if you are having a cesarean section. Breastfeeding should be discontinued 6 hours after administration of this medicine.
Driving and using machines
Do not drive or use machines until you are told it is safe to do so. Because Rocuronium Tamarang is administered as part of a general anesthetic, you may feel tired, weak, or dizzy for some time after. Your anesthesiologist can advise you on the likely duration of the effects.
Rocuronium Tamarang contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per vial/ampoule; this is essentially "sodium-free".
Dosage
Your anesthesiologist will calculate the dose of this medicine based on:
The usual dose is 0.6 mg per kg of body weight, and its effect lasts for 30 to 40 minutes.
How Rocuronium Tamarang is administered
Your anesthesiologist will give you Rocuronium Tamarang by intravenous injection (into a vein), either as single injections or as a continuous infusion (a drip).
This medicine is for single use only. Any unused solution for injection/infusion must be discarded.
If you are given more Rocuronium Tamarang than recommended
Because your anesthesiologist will be carefully monitoring your condition, it is unlikely that you will be given too much Rocuronium Tamarang. However, if this happens, your anesthesiologist will keep you breathing artificially (with a ventilator) until you can breathe on your own again. You will remain asleep while this happens.
Like all medicines, this medicine can cause side effects, although not everybody gets them. If these side effects occur while you are under anesthesia, your anesthesiologist will see them and treat them.
Uncommon
(may affect up to 1 in 100 people):
Rare
(may affect up to 1 in 10,000 people):
Frequency not known
(cannot be estimated from the available data):
If any of the side effects get worse, or if you notice any side effects not mentioned in this leaflet, tell your anesthesiologist or another doctor.
Reporting of side effects
If you experience any side effects, talk to your anesthesiologist or another doctor, even if it is a possible side effect not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date is the last day of the month shown.
Store in a refrigerator (2 °C - 8 °C).
Do not freeze.
Keep the vial/ampoule in the outer carton to protect it from light.
Rocuronium Tamarang can also be stored outside the refrigerator at a temperature not above 25° C for a maximum period of 12 weeks.
The medicine should be used immediately after opening the vial/ampoule.
Shelf-life of the diluted product: Chemical and physical in-use stability has been demonstrated after dilution with infusion fluids (see section 6.6) for 24 hours at 25 °C. From a microbiological point of view, the product should be used immediately.
If not used immediately, in-use storage times and conditions before use are the responsibility of the user and should not exceed 24 hours at 2-8 °C, unless the dilution has been carried out under validated aseptic conditions.
Do not use Rocuronium Tamarang if you notice that the solution is not clear or free of particles.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Rocuronium Tamarang
The active substance is rocuronium bromide.
Each ml of solution for injection and infusion contains 10 mg of rocuronium bromide.
Each vial/ampoule of 5 ml contains 50 mg of rocuronium bromide.
Each vial/ampoule of 10 ml contains 100 mg of rocuronium bromide.
The other ingredients are:
Sodium acetate trihydrate
Sodium chloride
Acetic acid 99% (for pH adjustment)
Acetic acid 30% (for pH adjustment)
Water for injection
Sodium hydroxide (for pH adjustment)
Appearance and packaging
Rocuronium Tamarang 10 mg/ml Solution for Injection and Infusion is a clear, colorless, or pale yellow-brown solution.
Vials/ampoules of 5 ml and 10 ml
Formats:
Packs of 10 vials/ampoules x 5 ml
Packs of 12 vials/ampoules x 5 ml
Packs of (6x 10) vials/ampoules x 5 ml
Packs of 10 vials/ampoules x 10 ml
Packs of (2x 10) vials/ampoules x 10 ml
Not all formats may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Tamarang, S.A.
Balmes 85 P 2
08008 Barcelona
Spain
Manufacturer
SOLUPHARM PHARMAZEUTISCHE ERZEUGNISSE GMBH
Industriestrasse 3
34212 Melsungen
Germany
This medicine is authorized in the Member States of the European Economic Area under the following names:
Germany | Rocuronium Inresa 10 mg/ml Injektionslösung/Infusionslösung |
Austria | Rocuroniumbromid Tamarang 10 mg/ml Injektionslösung/Infusionslösung |
Spain | Rocuronio Tamarang 10 mg/ml solución inyectable y para perfusión EFG |
Portugal | Brometo de Rocurónio Tamarang 10 mg/ml solução injectável |
Date of last revision of this leaflet:01/2024
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es